We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+4.21%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$418M
AUM Growth
+$84.2M
Cap. Flow
+$97.8M
Cap. Flow %
23.4%
Top 10 Hldgs %
66.46%
Holding
52
New
11
Increased
13
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$85.1M
2
GERN icon
Geron
GERN
+$6.69M
3
CBAY
Cymabay Therapeutics
CBAY
+$5.28M
4
KROS icon
Keros Therapeutics
KROS
+$5.03M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.87M

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$5.52M
2
TELA icon
TELA Bio
TELA
+$5.04M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$4.21M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.54M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLRN
1
DELISTED
ACELYRIN
SLRN
$86.9M 20.79%
+4,158,638
New +$85.1M
HROW icon
2
Harrow
HROW
$1.44B
$71.9M 17.19%
3,775,000
– –
OCUL icon
3
Ocular Therapeutix
OCUL
$2.38B
$29.8M 7.13%
5,780,000
-325,900
-5% -$1.94M
TELA icon
4
TELA Bio
TELA
$29.2M
$16M 3.83%
1,580,000
-492,813
-24% -$5.04M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$15.2M 3.64%
845,000
+59,206
+8% +$1.18M
KROS icon
6
Keros Therapeutics
KROS
$223M
$14.2M 3.39%
352,650
+114,650
+48% +$5.03M
BHVN icon
7
Biohaven
BHVN
$2.43B
$12.9M 3.09%
540,000
– –
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.75B
$12.1M 2.9%
735,000
– –
IDYA icon
9
IDEAYA Biosciences
IDYA
$4.03B
$9.75M 2.33%
415,000
+72,000
+21% +$1.48M
MOR
10
DELISTED
MorphoSys AG American Depositary Shares
MOR
$9.03M 2.16%
1,209,380
+15,380
+1% +$93.6K
PCVX icon
11
Vaxcyte
PCVX
$9.1B
$8.84M 2.11%
177,000
– –
ETON icon
12
Eton Pharmaceutcials
ETON
$1.79B
$7.97M 1.91%
2,285,000
+100,000
+5% +$368K
GERN icon
13
Geron
GERN
$983M
$7.54M 1.8%
+2,350,000
New +$6.69M
MRNS
14
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$6.79M 1.62%
625,000
-140,000
-18% -$1.2M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$6.48M 1.55%
720,000
-203,200
-22% -$1.87M
TARA icon
16
Protara Therapeutics
TARA
$236M
$6.44M 1.54%
2,692,594
– –
EWTX icon
17
Edgewise Therapeutics
EWTX
$4.8B
$6.32M 1.51%
815,000
+65,000
+9% +$548K
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
$6.21M 1.48%
+566,700
New +$5.28M
URGN icon
19
UroGen Pharma
URGN
$2.22B
$5.9M 1.41%
570,000
+65,000
+13% +$717K
TBPH icon
20
Theravance Biopharma
TBPH
$885M
$5.63M 1.35%
543,500
-2,804
-0.5% -$31K
THRX
21
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$5.57M 1.33%
597,500
+109,400
+22% +$1.08M
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$5.12B
$5.2M 1.24%
+217,000
New +$4.82M
NTLA icon
23
Intellia Therapeutics
NTLA
$1.84B
$4.89M 1.17%
+120,000
New +$4.87M
LQDA icon
24
Liquidia Corp
LQDA
$6.26B
$4.48M 1.07%
570,700
-4,500
-0.8% -$35K
LRMR icon
25
Larimar Therapeutics
LRMR
$421M
$4.35M 1.04%
1,390,000
-11,000
-0.8% -$44.9K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2023 Portfolio in Review

As of Q2 2023, Opaleye Management held 52 positions worth $418M, up 25% from $334M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Opaleye Management deployed $97.8M of net new capital in Q2 2023, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was ACELYRIN: 4,158,638 shares worth $86.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was TELA Bio, an estimated $5.04M trimmed.

  • Opaleye Management's largest Q2 2023 buy was ACELYRIN: 4,158,638 shares worth $86.9M.
  • Opaleye Management added most to Keros Therapeutics in Q2 2023, an estimated $5.03M increase.
  • Opaleye Management's biggest Q2 2023 reduction was TELA Bio, cutting an estimated $5.04M.
  • Opaleye Management fully exited Arcutis Biotherapeutics in Q2 2023, selling an estimated $5.52M.
  • Opaleye Management's ten largest holdings make up 66% of its $418M portfolio in Q2 2023.
  • Opaleye Management opened 11 new positions and closed 5 in Q2 2023.
  • Opaleye Management's portfolio value rose 25% quarter-over-quarter to $418M.

Based on Opaleye Management's 13F filing for Q2 2023, filed 14 Aug 2023.